Current Research - Cancer Treatment | Theranostics Australia

Current Research


Theranostics Australia is involved in several Hollywood Hospital ethics approved clinical trials in diagnostic and therapeutic cancer agents. Theranostics Australia is in part supported by the OMI Research Foundation whose aim is to foster research in molecular imaging and targeting therapies for people with Alzheimer’s disease, dementia or cancer.  Theranostics Australia will also aid its sister organisations, Diagnostic Nuclear Imaging and Oceanic Molecular Pty Ltd both based at Hollywood Hospital, to collect and analyse imaging data in order to identify trends which may lead to the prevention or control of those diseases.

Theranostics Australia are currently carrying out the following trials:

PSMA
Ga-68 PSMA in prostate cancer. [177Lu]PSMA in metastatic and palliative settings.
Pentixafor for Lung Cancer
Ga-68 pentixafor for lung cancer imaging. Pentixafor targets a receptor that is overexposed in several types of solid and hematopoietic malignancies.
Pentixafor for Myeloma
Ga-68 pentixafor for Myeloma imaging. Pentixafor targets a receptor that is overexposed in several types of solid and hematopoietic malignancies. [177Lu] Pentixather for Myeloma treatment. 
Octreotate in Neuroendocrine Tumours
Ga-68 octreotate for imaging of neuroendocrine tumours, and follow up therapy with [177Lu]octreotate.

If you are interested in collaborating or participating in any of these trials or have concepts and ideas for new trials, please contact us at reception@theranostics.com.au.